RASSF2 and breast cancer: Breast cancer cell lines were treated with the demethylating agent 5-aza-2′-deoxycytidine (5-azadC) to study the effect of restoring RASSF2 expression by lentivector technology on cell proliferation and the response to treatment in luminal and triple-negative breast cancer cell lines.